Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1953 1
1961 1
1962 1
1964 1
1967 1
1968 1
1969 1
1983 1
1987 1
1988 1
1994 1
1996 1
2000 1
2002 1
2003 2
2004 2
2006 2
2007 1
2008 1
2010 1
2011 1
2012 3
2013 1
2016 1
2020 2
2021 1
2022 2
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Rodriguez JE, et al. Among authors: goldschmidt v. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14. Expert Rev Anticancer Ther. 2022. PMID: 35815381 Review.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: goldschmidt v. Eur J Cancer. 2024 May 4;205:114075. doi: 10.1016/j.ejca.2024.114075. Online ahead of print. Eur J Cancer. 2024. PMID: 38733717 Review.
Antibody drug conjugates in older patients: State of the art.
Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C. Rached L, et al. Among authors: goldschmidt v. Crit Rev Oncol Hematol. 2024 Jan;193:104212. doi: 10.1016/j.critrevonc.2023.104212. Epub 2023 Nov 24. Crit Rev Oncol Hematol. 2024. PMID: 38007063 Review.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: goldschmidt v. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
Soil geochemistry.
GOLDSCHMIDT VM. GOLDSCHMIDT VM. Sci Prog. 1947 Oct;35(140):709-11. Sci Prog. 1947. PMID: 20267577 No abstract available.
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM. Ruste V, et al. Among authors: goldschmidt v. Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7. Eur J Cancer. 2021. PMID: 34627664
39 results